WuXi Biologics net profit surges 56 percent to 2.3 billion yuan

WuXi Biologics (2269) saw its first-half net profit surge 56 percent to 2.3 billion yuan (HK$2.5 billion).

Revenue for the period also increased by 16.1 percent to 9.95 billion yuan and the gross profit margin expanded by approximately 3.6 percent year-on-year. 

The group’s total backlog increased to US$20.3 billion (HK$158.34 billion) as of June 30, 2025, including US$11.4 billion service backlog and US$9 billion upcoming potential milestone fees, while the total backlog within three years increased to US$4.2 billion.